Sanofi, Amgen get solid FDA reviews on PSCK9 meds; J&J files for cancer med approval;

> Sanofi ($SNY) and Regeneron's ($REGN) anticholesterol drug Praluent effectively lowers "bad" LDL cholesterol and is reasonably well-tolerated, FDA staff reviewers said ahead of a Tuesday advisory panel meeting on the drug. Report

> Amgen's ($AMGN) PCSK9 cholesterol fighter Repatha lowered LDL with no red-flag safety problems, FDA staffers concluded in a review before Wednesday's advisory committee meeting on the med. Report

> Johnson & Johnson ($JNJ) said it applied for FDA approval for the "breakthrough"-designated blood cancer drug daratumumab, developed with Genmab. Report

> An FDA panel of experts backed approval of a controversial women's libido pill from Sprout, on the condition that the agency require postmarketing safety studies. Report

> London-based Four Communications snapped up the healthcare agency MSA Media--which counts Novartis ($NVS) and Bayer among its clients--to bolster its media-planning capabilities in the field. Report

And Finally... Botulinum toxin injections, sold as Botox and other brands, could be effective in two forms of neuropathy, a pain journal study found. Report

Suggested Articles

Sanofi's Dupixent is set to reach $12.5 billion in peak sales, Jefferies analysts wrote, affirming CEO Paul Hudson's focus on the immunology med.

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.

The FDA approved GlaxoSmithKline's Nucala to treat hypereosinophilic syndrome, making it the first biologic approved for that disease.